Skip to Main Content

Paper Details

Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenibâ¿¿+â¿¿trametinib versus nivolumab or pembrolizumab monotherapy.
Curr Med Res Opin
3
2018

Datasets

Release 1.2